A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
Automated Immunohistochemical Assay for Estrogen Receptor Status in Breast Cancer Using Monoclonal Antibody CC4-5 on the Ventana ES
American Journal of Clinical Pathology
Determination of breast cancer estrogen receptor (ER) status as a predictor of tumor response to adjuvant endocrine therapy remains a mainstay of breast cancer management. Recent second generation anti-ER antibodies and new epitope retrieval methods have produced paraffinbased immunohistochemical results that correlate closely with the dextran-coated charcoal (DCC) assay and appear to represent a superior method of ER assay. The authors determined the ER status of 103 invasive breast cancers bydoi:10.1093/ajcp/106.3.332 pmid:8816590 fatcat:gulmpoubh5ga5hnxwiccbvonca